Trial Profile
Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Oct 2019
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics; Registrational
- Acronyms UNCOVER-A
- Sponsors Eli Lilly and Company
- 24 Dec 2016 Results of an integrated analysis of UNCOVER-1, UNCOVER-2, UNCOVER-3, UNCOVER-A, UNCOVER-J and two other phase 1 and phase 2 studies published in the Journal of the American Academy of Dermatology.
- 08 Mar 2016 Results of sub-group analysis (n=102) presented at the 74th Annual Meeting of the American Academy of Dermatology.
- 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology